The Globe and Mail reports in its Tuesday, Dec. 23, edition that National Bank Financial analyst Zachary Evershed continues to rate Savaria "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Evershed jacked his share target up by $4 to $30, matching the consensus. Mr. Evershed sees Savaria "underindexed" in Western Europe, believing the region is a potential source of significant gains for the at-home accessibility equipment manufacturer. Mr. Evershed says in a note: "Though a tumultuous geopolitical environment saw Savaria's initial growth goal checked back to $925-million [from $1-billion], the company is on track to hit the S1 20-per-cent margin target and can declare Mission Accomplished. Therefore, ahead of the company's second investor day in April 2026, at which management will divulge new long-term targets, we take this opportunity to speculate on the drivers of the next leg of operational improvements. Tailwinds continue to blow in patient care, as we previously explored, supported by accelerating demographics, allowing us to turn our attention back to accessibility, and Europe in particular."